menu search

LXRX / U.S. FDA approves Lexicon Pharma's heart failure drug

U.S. FDA approves Lexicon Pharma's heart failure drug
The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc's drug as a broad treatment for all heart failure patients, including adults with type 2 diabetes, the company said on Friday. Read More
Posted: May 26 2023, 16:14
Author Name: Reuters
Views: 111573

LXRX News  

Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts

By Zacks Investment Research
October 11, 2023

Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts

A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The more_horizontal

Why Shares of Lexicon Pharmaceuticals Are Up Tuesday

By The Motley Fool
October 10, 2023

Why Shares of Lexicon Pharmaceuticals Are Up Tuesday

Lexicon just launched heart failure therapy Inpefa this year. The drug was approved by the FDA in May. more_horizontal

Lexicon Pharmaceuticals shares rise on Express Scripts support for Inpefa heart drug

By Proactive Investors
October 10, 2023

Lexicon Pharmaceuticals shares rise on Express Scripts support for Inpefa heart drug

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares jumped 9% in Tuesday pre-market trading after it announced that its Inpefa heart failure drug has more_horizontal

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 3, 2023

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2023 Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Carrie Siragusa - Vice Pr more_horizontal

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 3, 2023

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares more_horizontal

Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023

By GlobeNewsWire
July 28, 2023

Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023

THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial re more_horizontal

Penny Stocks To Buy? 4 To Watch With Big News Now

By PennyStocks
June 15, 2023

Penny Stocks To Buy? 4 To Watch With Big News Now

Are you on the hunt for the next big thing? Ready to catch the wave before it crests? more_horizontal

Why Lexicon Pharmaceuticals Stock Crashed This Week

By The Motley Fool
June 2, 2023

Why Lexicon Pharmaceuticals Stock Crashed This Week

With a new heart failure drug in hand, Lexicon Pharmaceuticals decided to raise capital this week, causing its shares to fall by double digits. The co more_horizontal


Search within

Pages Search Results: